secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2026-08-14T12:35:24+00:00
Accession:  0001437749-26-027837
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene Q2 net loss $13.4M; NDA for CNM-Au8 in ALS expected early Q4 2026
-----------------------------------------------------------------------

- NDA for CNM-Au8 in ALS under accelerated approval expected early Q4 2026; FDA confirmed data may support submission.
- Cash $9.7M at June 30 vs $5.2M at Dec 31; runway through late Q4 2026.
- Net loss $13.4M ($1.08/share) vs $7.4M ($0.78) in Q2 2025; other expense $8.1M on warrant/derivative fair value.
- R&D flat at $3.5M; G&A down to $1.9M from $2.4M.
- Closed $7M offering; extended convertible debt maturities to Aug 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/0001437749-26-027837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/clnn20260524_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer